Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5948549 | Atherosclerosis | 2012 | 7 Pages |
Abstract
⺠We identified two new mutations of PCSK9: p.Leu108Arg and p.Asp35Tyr in two French families with hypercholesterolemia. ⺠In vitro studies of their consequences on the activity of PCSK9 on cell surface levels of LDLR were analyzed. ⺠p.Leu108Arg exhibited a â¼2-fold enhanced degrading activity towards the LDLR clearly resulting in a gain-of-function. ⺠p.Asp35Tyr created a novel Tyr-sulfation site, which may enhance the intracellular activity of PCSK9. ⺠These data further contribute to the characterization of PCSK9 mutations and to better understanding of their impact.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Marianne Abifadel, Maryse Guerin, Suzanne Benjannet, Jean-Pierre Rabès, Wilfried Le Goff, Zélie Julia, Josée Hamelin, Valérie Carreau, Mathilde Varret, Eric Bruckert, Laurent Tosolini, Olivier Meilhac, Philippe Couvert, Dominique Bonnefont-Rousselot,